海普瑞(002399)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002399 海普瑞

已收盘 04-30 15:00:00

{"stockData":{"symbol":"002399","market":"SZ","secType":"STK","nameCN":"海普瑞","latestPrice":10.88,"timestamp":1745996583000,"preClose":10.88,"halted":0,"volume":2669761,"delay":0,"changeRate":0,"floatShares":1247000000,"shares":1467000000,"eps":0.4419,"marketStatus":"已收盘","change":0,"latestTime":"04-30 15:00:00","open":10.89,"high":11,"low":10.87,"amount":29212100,"amplitude":0.0119,"askPrice":10.88,"askSize":13,"bidPrice":10.87,"bidSize":145,"shortable":0,"etf":0,"ttmEps":0.4419,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1746495000000},"marketStatusCode":5,"adr":0,"adjPreClose":10.88,"symbolType":"stock","openAndCloseTimeList":[[1745976600000,1745983800000],[1745989200000,1745996400000]],"highLimit":11.97,"lowLimit":9.79,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1467296204,"isCdr":false,"pbRate":1.3,"roa":"--","peRate":24.620955,"roe":"1.28%","epsLYR":0.4408,"committee":0.037433,"marketValue":15964000000,"turnoverRate":0.0021,"status":2,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2025-05-06。","hkstockBrief":{"symbol":"09989","market":"HK","secType":"STK","nameCN":"海普瑞","latestPrice":4.46,"timestamp":1746173305039,"preClose":4.45,"halted":0,"volume":77500,"delay":0,"premium":"-61.86"},"floatMarketCap":13570000000},"requestUrl":"/m/hq/s/002399/tweets","defaultTab":"tweets","newsList":[{"id":"2529960071","title":"海普瑞(002399.SZ)发布一季度业绩，归母净利润1.57亿元，同比增长1.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529960071","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529960071?lang=zh_cn&edition=full","pubTime":"2025-04-24 19:22","pubTimestamp":1745493778,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海普瑞(002399.SZ)发布2025年一季度报告，第一季度，公司实现营业收入13.94亿元，同比增长1.53%。归属于上市公司股东的净利润1.57亿元，同比增长1.00%。归属于上市公司股东的扣除非经常性损益的净利润1.89亿元，同比增长20.27%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1284178.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09989","002399"],"gpt_icon":0},{"id":"2529604530","title":"海普瑞(09989)：Ivenoxin获南非健康产品监管局上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2529604530","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529604530?lang=zh_cn&edition=full","pubTime":"2025-04-24 18:24","pubTimestamp":1745490240,"startTime":"0","endTime":"0","summary":"海普瑞发布公告，公司全资子公司深圳市天道医药有限公司生产的依诺肝素钠注射液已获得南非健康产品监管局上市许可。此次获批意味着集团依诺肝素钠制剂可进入南非市场销售，进一步提升了集团依诺肝素钠制剂在全球的市场份额。董事会认为，这是集团制剂业务国际化布局的又一重要成果，再次印证了集团开拓海外市场的能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-04-24/doc-ineuhiqv2857399.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["002399","BK0188","BK0070","09989","BK1191","BK0239"],"gpt_icon":0},{"id":"2529606213","title":"海普瑞(09989)发布一季度业绩，归母净利润1.57亿元，同比增长1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529606213","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529606213?lang=zh_cn&edition=full","pubTime":"2025-04-24 18:23","pubTimestamp":1745490195,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海普瑞(09989)发布2025年第一季度业绩，营业收入13.94亿元，同比增长1.53%;归属于上市公司股东的净利润1.57亿元，同比增长1%;基本每股收益0.1067元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1284097.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002399","09989"],"gpt_icon":0},{"id":"2529603247","title":"海普瑞最新公告：依诺肝素钠注射液获得南非药品注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2529603247","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529603247?lang=zh_cn&edition=full","pubTime":"2025-04-24 18:01","pubTimestamp":1745488878,"startTime":"0","endTime":"0","summary":"海普瑞公告称，全资孙公司天道医药收到南非卫生产品管理局签发的依诺肝素钠注射液批准通知。许可有效期为五年。本次获批将进一步提升公司依诺肝素钠制剂在全球的市场占有率，是公司制剂业务国际化布局的重要成果。截至公告日，该产品已在全球超过50个国家及地区获批上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042400030864.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09989","BK0188","BK0070","BK0239","BK1191","002399"],"gpt_icon":0},{"id":"2517193729","title":"海普瑞：公司将持续加强市值管理工作争取为股东带来更好回报","url":"https://stock-news.laohu8.com/highlight/detail?id=2517193729","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517193729?lang=zh_cn&edition=full","pubTime":"2025-03-05 20:51","pubTimestamp":1741179096,"startTime":"0","endTime":"0","summary":"证券之星消息，海普瑞(002399)03月04日在投资者关系平台上答复投资者关心的问题。投资者提问：工资如何维护投资者的利益？是否看好公司未来前景？能否推行员工持股股计划四期，能否回购公司股份注销？能否推动高管增持股份计划？能否2024年度分红扩股？海普瑞回复：您好，公司始终坚持聚焦核心主业，提升公司内在价值，我们将持续加强市值管理工作，促进公司投资价值合理反映公司质量，争取为股东带来更好的回报。谢谢您的关注。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030500038393.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","002399","09989","BK1191","BK0188","BK0239"],"gpt_icon":0},{"id":"2517195619","title":"海普瑞：公司专注主业已建立全球销售网络和全肝素产业链领先优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2517195619","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517195619?lang=zh_cn&edition=full","pubTime":"2025-03-05 20:51","pubTimestamp":1741179092,"startTime":"0","endTime":"0","summary":"证券之星消息，海普瑞03月04日在投资者关系平台上答复投资者关心的问题。公司是否会进行投资？海普瑞回复：您好，公司专注主业，在肝素领域，我们已建立全球销售网络和全肝素产业链垂直打通的领先优势，核心产品依诺肝素钠制剂远销逾40个国家及地区。同时，我们持续探索合适机遇，如建立并推进与正大天晴、永太药业的商业合作，助力中国药企出海。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030500038389.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002399","BK0239","09989","BK1191","BK0188","BK0070"],"gpt_icon":0},{"id":"2514104103","title":"海普瑞收盘下跌3.16%，最新市净率1.37，总市值166.24亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514104103","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514104103?lang=zh_cn&edition=full","pubTime":"2025-02-28 16:56","pubTimestamp":1740733000,"startTime":"0","endTime":"0","summary":"2月28日，海普瑞今日收盘11.33元，下跌3.16%，最新市净率1.37，总市值166.24亿元。消息面上，海普瑞4月23日接待线上参与公司2023年年度业绩说明会的全体投资者等1家机构调研，上市公司接待人员包括董事长李锂,董事、总经理单宇,独立董事易铭,财务总监陈娟,董事会秘书钱风奇。最新一期业绩显示，2024年三季报，公司实现营业收入40.69亿元，同比0.14%；净利润7.80亿元，同比444.89%，销售毛利率33.20%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/02/28165648456446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","BK0188","BK0070","09989","002399","BK0239"],"gpt_icon":0},{"id":"2514838622","title":"【海普瑞(09989.HK)：ENOPARIN获得阿根廷批准】海普瑞(09989.HK)发布公告，旗下全资附属公司深圳市天道医药有限公司生产的Enoparin(集团依诺肝素钠注射液领先药物之一)已获得阿根廷国家药品、食品和医疗器械管理局(ANMAT)批准上市销售。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514838622","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514838622?lang=zh_cn&edition=full","pubTime":"2025-02-26 18:57","pubTimestamp":1740567442,"startTime":"0","endTime":"0","summary":"海普瑞(09989.HK)发布公告，旗下全资附属公司深圳市天道医药有限公司生产的Enoparin(集团依诺肝素钠注射液领先药物之一)已获得阿根廷国家药品、食品和医疗器械管理局(ANMAT)批准上市销售。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/26185748407961.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["09989","BK0188","BK0070","BK0239","BK1191","BK1515","002399","159883","BK1583","09997","BK1574","09939","BK1222","BK1161","159938","09996","BK1100"],"gpt_icon":0},{"id":"2514838336","title":"海普瑞(09989)：ENOPARIN获得阿根廷批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2514838336","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514838336?lang=zh_cn&edition=full","pubTime":"2025-02-26 18:50","pubTimestamp":1740567032,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海普瑞(09989)发布公告，旗下全资附属公司深圳市天道医药有限公司生产的Enoparin(集团依诺肝素钠注射液领先药物之一)已获得阿根廷国家药品、食品和医疗器械管理局(ANMAT)批准上市销售。本次获批，代表集团海普瑞的依诺肝素钠制剂将会于阿根廷市场进行销售，将进一步提升集团依诺肝素钠制剂在全球的市场占有率。公司认为本次核准是集团制剂业务实施国际化布局的另一个重要成果，再次证明集团进军海外市场的能力。未来，集团将会持续发力，加速集团拓展全球市场的进程及销售通路建设，为后续进一步加强海外市场发展做好铺垫。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1254812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0070","002399","BK0188","BK1191","09989","BK0239"],"gpt_icon":0},{"id":"2514880098","title":"海普瑞(002399.SZ)：依诺肝素钠注射液获阿根廷药品注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2514880098","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514880098?lang=zh_cn&edition=full","pubTime":"2025-02-26 18:47","pubTimestamp":1740566824,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海普瑞 公告，公司全资孙公司深圳市天道医药有限公司近期收到阿根廷国家药品、食品和医疗器械管理局签发的依诺肝素钠注射液批准通知。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1254805.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002399","BK1191","BK0070","BK0188","09989","BK0239"],"gpt_icon":0},{"id":"2514807318","title":"【海普瑞：依诺肝素钠注射液获得阿根廷药品注册批件】金融界2月26日消息，深圳市海普瑞药业集团股份有限公司全资孙公司天道医药近期收到阿根廷国家药品、食品和医疗器械管理局签发的依诺肝素钠注射液批准通知。产品剂型为注射液，规格包括0.2ml:20mg、0.4ml:40mg、0.6ml:60mg、0.8ml:80mg，适应症多样，许可有效期五年。本次获批代表海普瑞的依诺肝素钠制剂可在阿根廷市场销售，将提升其在全球的市场占有率，是集团制剂业务国际化布局的重要成果。截至本公告日，公司依诺肝素钠制剂在全球超过40个国家及地区获批上市。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514807318","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514807318?lang=zh_cn&edition=full","pubTime":"2025-02-26 18:41","pubTimestamp":1740566513,"startTime":"0","endTime":"0","summary":"金融界2月26日消息，深圳市海普瑞药业集团股份有限公司全资孙公司天道医药近期收到阿根廷国家药品、食品和医疗器械管理局签发的依诺肝素钠注射液批准通知。产品剂型为注射液，规格包括0.2ml:20mg、0.4ml:40mg、0.6ml:60mg、0.8ml:80mg，适应症多样，许可有效期五年。本次获批代表海普瑞的依诺肝素钠制剂可在阿根廷市场销售，将提升其在全球的市场占有率，是集团制剂业务国际化布局的重要成果。截至本公告日，公司依诺肝素钠制剂在全球超过40个国家及地区获批上市。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/26184148407494.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1515","09939","BK1161","09997","002399","159883","09989","09996","BK0239","159938","BK0188","BK1100","BK1191","BK1222","BK1574","BK1583","BK0070"],"gpt_icon":0},{"id":"2514805068","title":"海普瑞：依诺肝素钠注射液获阿根廷批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2514805068","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514805068?lang=zh_cn&edition=full","pubTime":"2025-02-26 18:39","pubTimestamp":1740566396,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["09939","09989","BK1222","BK1515","BK1100","BK1574","09996","159883","BK1161","002399","159938","BK1583","BK1191","BK0239","BK0070","09997","BK0188"],"gpt_icon":0},{"id":"2512854450","title":"A股创新药板块盘初拉升，仟源医药大涨11%，康龙化成、海普瑞涨超5%，泰格医药、北陆药业、冠昊生物跟涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512854450","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512854450?lang=zh_cn&edition=full","pubTime":"2025-02-20 09:34","pubTimestamp":1740015296,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1141","BK0239","BK1583","BK0046","06978","399300","159982","300759","BK1576","BK0042","03759","BK1191","BK0251","300254","BK0188","BK1161","BK0086","LU1146622755.USD","BK0216","159992","LU1820825898.SGD","002399","BK0060","BK0028","BK0114","03347","BK0174","300016","BK0070","09989","300347","BK1574","300238","BK0077"],"gpt_icon":0},{"id":"2512120563","title":"2月19日海普瑞（002399）涨停分析：创新药突破、CDMO业务及汇率驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2512120563","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512120563?lang=zh_cn&edition=full","pubTime":"2025-02-19 15:47","pubTimestamp":1739951240,"startTime":"0","endTime":"0","summary":"证券之星消息，海普瑞2月19日涨停收盘，收盘价11.29元。该股于10点55分涨停，未打开涨停，截止收盘封单资金为1933.07万元，占其流通市值0.14%。2月19日的资金流向数据方面，主力资金净流入3972.21万元，占总成交额29.04%，游资资金净流出1229.02万元，占总成交额8.99%，散户资金净流出2743.19万元，占总成交额20.05%。近5日资金流向一览见下表：该股为化学原料药，新冠疫苗，医药概念热股，当日化学原料药概念上涨0.92%，新冠疫苗概念上涨0.84%，医药概念上涨0.82%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025021900023318.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","002399","BK0239","09989","159992","BK1191","BK1574","BK0188","06978","BK0070"],"gpt_icon":0},{"id":"2512240011","title":"2月19日海普瑞涨停分析：化学原料药，新冠疫苗，医药概念热股","url":"https://stock-news.laohu8.com/highlight/detail?id=2512240011","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512240011?lang=zh_cn&edition=full","pubTime":"2025-02-19 15:24","pubTimestamp":1739949843,"startTime":"0","endTime":"0","summary":"证券之星消息，海普瑞2月19日涨停收盘，收盘价11.29元。该股于10点55分涨停，未打开涨停，截止收盘封单资金为1933.07万元，占其流通市值0.14%。2月19日的资金流向数据方面，主力资金净流入3972.21万元，占总成交额29.04%，游资资金净流出1229.02万元，占总成交额8.99%，散户资金净流出2743.19万元，占总成交额20.05%。近5日资金流向一览见下表：该股为化学原料药，新冠疫苗，医药概念热股，当日化学原料药概念上涨0.92%，新冠疫苗概念上涨0.84%，医药概念上涨0.82%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025021900020841.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","09989","BK0188","BK0070","BK1574","002399","BK1191","BK1161","159938","09939","BK1515","BK0239"],"gpt_icon":0},{"id":"2512149143","title":"异动快报：海普瑞（002399）2月19日10点55分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2512149143","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512149143?lang=zh_cn&edition=full","pubTime":"2025-02-19 11:00","pubTimestamp":1739934051,"startTime":"0","endTime":"0","summary":"证券之星2月19日盘中消息，10点55分海普瑞触及涨停板。目前价格11.29，上涨10.04%。其所属行业化学制药目前上涨。该股为化学原料药，新冠疫苗，医药概念热股，当日化学原料药概念上涨0.48%，新冠疫苗概念上涨0.41%，医药概念上涨0.31%。2月18日的资金流向数据方面，主力资金净流出661.22万元，占总成交额16.71%，游资资金净流入434.86万元，占总成交额10.99%，散户资金净流入226.35万元，占总成交额5.72%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025021900014604.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09989","BK0188","BK1191","BK0070","BK0239","002399"],"gpt_icon":0},{"id":"2512733149","title":"海普瑞(09989)股价显著上升11.083%，现价港币$4.41","url":"https://stock-news.laohu8.com/highlight/detail?id=2512733149","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512733149?lang=zh_cn&edition=full","pubTime":"2025-02-19 10:55","pubTimestamp":1739933700,"startTime":"0","endTime":"0","summary":"[上升股]海普瑞(09989) 股价在上午10:55比前收市价显著上升11.083%，现股价为港币$4.41。至目前为止，今日最高价为$4.41，而最低价为$3.94。总成交量为503.8万股，总成交金额为港币$2.126千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152549604_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152549604_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2502191201/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09989","002399","BK1191","BK0070","BK0188","BK0239"],"gpt_icon":0},{"id":"2512149392","title":"港股异动 | 海普瑞(09989)早盘涨超8% 抗肿瘤药H1710获批临床 新建制剂生产线获得GMP证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2512149392","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512149392?lang=zh_cn&edition=full","pubTime":"2025-02-19 10:54","pubTimestamp":1739933671,"startTime":"0","endTime":"0","summary":"消息面上，海普瑞公布，公司于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，批准注射用H1710开展临床试验。据悉，H1710是公司自主研发的候选药物，公司具有H1710的全球开发及商业化权益。公司指，海普瑞坪山园区的新建预灌封制剂生产线项目去年已完成并首次通过欧盟GMP认证。根据欧盟成员国之间的GMP互认制度，本次通过GMP认证表明本次接受认证的生产线已符合欧盟GMP标准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1251481.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09989","BK0188","BK1191","BK0070","BK0239","002399"],"gpt_icon":0},{"id":"2512139341","title":"海普瑞(09989.HK)候选药物H1710临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2512139341","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512139341?lang=zh_cn&edition=full","pubTime":"2025-02-18 16:34","pubTimestamp":1739867640,"startTime":"0","endTime":"0","summary":"海普瑞(09989.HK) 公布，于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，批准公司自主研发的候选药物注射用H1710开展临床试验，适应症为晚期实体瘤。H1710是一种高效高选择性的乙酰肝素酶抑制剂，海普瑞指，临床前研究已表明H1710通过抑制乙酰肝素酶的活性和表达表现出抗肿瘤药理活性，在多种肿瘤动物模型中均展示出显著的抑瘤作用。截至目前，于全球范围内尚无同一分子机制的同类产品上市。(gc/j)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20210324165849609_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20210324165849609_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1418152/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0239","BK0188","03347","BK1141","BK0070","002399","BK1191","09989","BK1583","BK1576"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1746293147758,"stockEarnings":[{"period":"1week","weight":-0.0118},{"period":"1month","weight":-0.0207},{"period":"3month","weight":0.0762},{"period":"6month","weight":0.0083},{"period":"1year","weight":0.0502},{"period":"ytd","weight":0.0178}],"compareEarnings":[{"period":"1week","weight":-0.0053},{"period":"1month","weight":-0.017},{"period":"3month","weight":0.0087},{"period":"6month","weight":0.0021},{"period":"1year","weight":0.0561},{"period":"ytd","weight":-0.0217}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳市海普瑞药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"0人","perCapita":"--","listingDate":"2010-05-06","address":"广东省深圳市南山区松坪山郎山路21号","registeredCapital":"146729万元","survey":"　　深圳市海普瑞药业集团股份有限公司的主营业务是肝素产业链，生物大分子CDMO和创新药物的投资，开发及商业化。公司的主要产品是依诺肝素钠制剂、肝素钠、依诺肝素钠原料药、大分子药物CDMO服务。公司旗下依诺肝素钠制剂自2016年通过集中审批程序（CP）在欧洲药品管理局（EMA）获得批准后，2020年在售全部5个规格率先通过国内仿制药质量和疗效一致性评价。凭借卓越的产品质量和稳定的疗效，公司旗下依诺肝素钠制剂累计出口量稳居国内前列。","listedPrice":148},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海普瑞(002399)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海普瑞(002399)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海普瑞,002399,海普瑞股票,海普瑞股票老虎,海普瑞股票老虎国际,海普瑞行情,海普瑞股票行情,海普瑞股价,海普瑞股市,海普瑞股票价格,海普瑞股票交易,海普瑞股票购买,海普瑞股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海普瑞(002399)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海普瑞(002399)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}